Chen Liqian, Zhou Xinghong, Deng Yijian, Yang Ying, Chen Xiaohu, Chen Qinghong, Liu Yanyan, Fu Xiuqiong, Kwan Hiu Yee, You Yanting, Jin Wen, Zhao Xiaoshan
School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, China.
School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
J Ethnopharmacol. 2023 Jan 10;300:115705. doi: 10.1016/j.jep.2022.115705. Epub 2022 Sep 12.
Zhenwu Decoction (ZWD) is a traditional Chinese medicine (TCM) formula which has wide scope of indications related to Yang deficiency and dampness retention in TCM syndrome. Cardiac hypertrophy can induce similar symptoms and signs to the clinical features of Yang deficiency and dampness retention syndrome. ZWD can increase the left ventricular ejection fraction, reduce cardiac hypertrophy of patients with chronic heart failure. However, its underlying pharmacological mechanism remains unclear.
The study aimed to confirm the protective effects of ZWD on cardiac hypertrophy and explore the underlying mechanisms.
The potential targets and pathways of ZWD in cardiac hypertrophy were highlighted by network pharmacology and validated by mechanistic and functional studies.
Our network pharmacology analysis suggests that the protective effects of ZWD on cardiac hypertrophy are related to cyclic guanosine monophosphate (cGMP) - protein kinase G (PKG) pathway. Subsequent animal studies showed that ZWD significantly ameliorated cardiac function decline, cardiac hypertrophy, cardiac fibrosis and cardiomyocyte apoptosis. To explore the underlying mechanisms of action, we performed Western blotting, immunohistochemical analysis, and detection of inflammatory response and oxidative stress. Our results showed that ZWD activated the soluble guanylate cyclase (sGC) - cGMP - PKG signaling pathway. The sGC inhibitor ODQ that blocks the sGC-cGMP-PKG signaling pathway in zebrafish abolished the protective effects of ZWD, suggesting sGC-cGMP-PKG is the main signaling pathway mediates the protective effect of ZWD in cardiac hypertrophy. In addition, three major ingredients from ZWD, poricoic acid C, hederagenin and dehydrotumulosic acid, showed a high binding energy with prototype sGC.
ZWD reduces oxidative stress and inflammation and exerts cardioprotective effects by activating the sGC-cGMP-PKG signaling pathway.
真武汤(ZWD)是一种中药方剂,在中医证候中具有与阳虚和湿滞相关的广泛适应症。心脏肥大可诱发与阳虚湿滞证临床特征相似的症状和体征。真武汤可提高慢性心力衰竭患者的左心室射血分数,减轻心脏肥大。然而,其潜在的药理机制仍不清楚。
本研究旨在证实真武汤对心脏肥大的保护作用并探索其潜在机制。
通过网络药理学突出真武汤在心脏肥大中的潜在靶点和途径,并通过机制和功能研究进行验证。
我们的网络药理学分析表明,真武汤对心脏肥大的保护作用与环磷酸鸟苷(cGMP)-蛋白激酶G(PKG)途径有关。随后的动物研究表明,真武汤显著改善心脏功能下降、心脏肥大、心脏纤维化和心肌细胞凋亡。为了探索潜在的作用机制,我们进行了蛋白质免疫印迹、免疫组织化学分析以及炎症反应和氧化应激检测。我们的结果表明,真武汤激活了可溶性鸟苷酸环化酶(sGC)-cGMP-PKG信号通路。在斑马鱼中阻断sGC-cGMP-PKG信号通路的sGC抑制剂ODQ消除了真武汤的保护作用,表明sGC-cGMP-PKG是介导真武汤对心脏肥大保护作用的主要信号通路。此外,真武汤的三种主要成分,茯苓酸C、常春藤皂苷元和去氢土莫酸,与原型sGC显示出高结合能。
真武汤通过激活sGC-cGMP-PKG信号通路减轻氧化应激和炎症,发挥心脏保护作用。